Plus Therapeutics shareholders approve reverse stock split authorization and up to $50M issuance to Lincoln Park

PLUS THERAPEUTICS, INC.

All six director nominees were elected to the board for a term expiring at the 2026 annual meeting.
Approved potential issuance of up to $50M common stock plus $1M commitment fee to Lincoln Park Capital Fund.
Board authorized to effect a reverse stock split at a ratio between 1:2 and 1:250 within 12 months.
Advisory vote on executive compensation passed with 16,714,842 votes for and 858,028 against.
Fifth amendment and restatement of the 2020 Stock Incentive Plan was approved by stockholders.

item 5.07

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-179012
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2025-08-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.327260+00:00
generated_at: 2026-05-17T14:15:29.270538+00:00
sec_items: ["5.07"]
event_type: other_material
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-179012
json_url: https://secwatch.observer/filing/0001193125-25-179012.json
markdown_url: https://secwatch.observer/filing/0001193125-25-179012.md
text_url: https://secwatch.observer/filing/0001193125-25-179012.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312525179012/0001193125-25-179012-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312525179012/d71976d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-179012

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.